Cite
HARVARD Citation
Kimmich, C. et al. (2021). Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American journal of hematology. 96 (7), pp. E253-E257. [Online].